Michael Tsatsos

Dr. Michael Tsatsos

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2016 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
CMCheryl MacGregor
Cheryl MacGregor
IAIoannis Athanasiadis
Ioannis Athanasiadis
MMMarilita M Moschos
Marilita M Moschos
PHParwez Hossain
Parwez Hossain
DADavid Anderson
David Anderson

18 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAris Konstantopoulos
Aris Konstantopoulos
MCMaria del Mar Cendra
Maria del Mar Cendra
Michael TsatsosMichael Tsatsos
Michael Tsatsos
MEMariam Elabiary
Mariam Elabiary
MCMyron Christodoulides
Myron Christodoulides
PHParwez Hossain
Parwez Hossain
Bacterial keratitis (BK) is an ocular disorder associated with poor visual prognosis. Quantification of the associated inflammatory response may provide insight into the pathogenesis of BK and guide treatment options. In this exploratory study, we evaluated 45 BK patients and 20 healthy controls by optical coherence tomography and pro-inflammatory tear cytokine analysis. The aim was to quantify the differential morphological and cytokine inflammatory response between Gram-negative and Gram-positive BK and to determine the diagnostic value of corneal thickness (CT) and infiltrate thickness (IT) in distinguishing Gram−ve BK in a clinical cohort. Greater CT and IT, at clinical presentation, were indicative of Gram−ve infection with values detected of ≥ 950 μm and ≥ 450 μm, respectively. Combination of these CT and IT values had a 100% sensitivity and 83.3% specificity as a diagnostic indicator of Gram−ve infection. Similarly, there were higher levels of IL-1β, IL-6 and IL-8 cytokines were quantified in keratitis caused by Gram-negative bacteria. Among the different tear cytokines analysed, a significant reduction after three days of treatment was detected for pro-inflammatory cytokines IL-1β, IL-2, IL-6, IL-8 and TNF-α, prior to starting with the administration of steroid drops. Overall, this study shows the potential value of serial OCT and tear cytokine measurements in the management of BK.

21 June 2017 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
CMCheryl MacGregor
Cheryl MacGregor
IAIoannis Athanasiadis
Ioannis Athanasiadis
MMMarilita M Moschos
Marilita M Moschos
SJSazan Jameel
Sazan Jameel
DADavid Anderson
David Anderson

Verified
Journal Article
Open access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
CDChryseis Delimitrou
Chryseis Delimitrou
ITIoannis Tsinopoulos
Ioannis Tsinopoulos
NZNikolaos Ziakas
Nikolaos Ziakas
Ocular surface squamous neoplasia (OSSN) includes a variety of ocular surface tumors ranging from mild epithelial dysplasia to invasive squamous cell carcinoma. OSSN is one of the most frequent non-pigmented malignancies of the ocular surface. Debate persists between surgical excision and medical management concerning the optimal regimen for OSSN treatment, with surgical excision continuing to be the recognized standard of care in contemporary medicine. Medical and conservative therapy techniques have advanced significantly in recent years, leading to widespread use in everyday ophthalmology practice. This study aims to look into the efficacy of current treatment options for conjunctival squamous cell carcinoma and to evaluate the available evidence for the most up-to-date approach for the management of the disease.

2 May 2014 in Eye
Verified
Journal Article
Open access
CMC MacGregor
C MacGregor
Michael TsatsosMichael Tsatsos
Michael Tsatsos
PHP Hossain
P Hossain
Collagen cross-linking (CXL) was introduced in the late nineties and was later adopted as a treatment option for keratoconus, pellucid marginal degeneration, and post-LASIK ectasia in 2003.1, 2, 3 CXL is the only treatment modality for these conditions that addresses the underlying stromal weakening and thus halts disease progression. Recently, accelerated CXL was proposed as an alternative technique, whereby corneal stiffening can be achieved with higher fluence and reduced overall exposure time.4 The Bunsen–Roscoe reciprocity law, the basis for accelerated CXL, is valid within a certain range.5 Determining what this range is for the cornea and how it translates to treatment settings and outcomes is still not known. Wernli et al6 performed an ex vivo study and found that at illumination intensity of 45 mW/cm2 and time exposure of <2 min, no corneal stiffening was achieved. On the basis of the experimental data presented by Richoz et al,7 CXL requires the presence of oxygen for corneal stiffening to occur. Time exposure is perhaps more significant than we initially suspected, as at reduced time exposure, where oxygen utilisation is compromised, corneal stiffening is in turn hindered.6, 7 Moreover, the safety of a higher fluence, even for a short duration, is yet to be demonstrated and there is concern of long-term irradiation toxicity and greater risk of endothelial damage.8, 9 In the short term, more keratocyte apoptosis has been observed in corneas that have undergone accelerated CXL compared with conventional CXL.10 The clinical significance of this is still unknown but suggests that as a procedure, accelerated CXL is harsher to the cornea. In conventional CXL, a demarcation line, which demonstrates the depth of treatment, is seen at 300–350 μm.11 A confocal microscopy study by Touboul et al10 showed that with accelerated CXL, the demarcation line lies anterior at an average depth of 100–150 μm, considerably less than that in conventional CXL. With keratoconus being a posterior corneal disease, at least in its early stages, the CXL depth reached by accelerated CXL may not suffice for effective treatment.12 In paediatric patients, treatment with conventional CXL is advocated early before established disease progression, as conventional CXL has been found to be safe and effective.13, 14, 15 There is no literature available, at least at present, reporting the use of accelerated CXL in paediatric patients. Perhaps the greatest concern regarding accelerated CXL is that the evidence for its efficacy is powered by case series and small studies, with shorter follow-up than conventional CXL.10, 16, 17, 18 The evidence supporting conventional CXL is extensive, including its successful use in thin corneas (<400 μm) with the recommended use of hypoosmolar riboflavin.17, 18, 19, 20 O’Brart et al21 published long-term results for conventional CXL that reported similar treatment efficacy and safety to the Siena Eye Cross study but also noted that the cornea continues to flatten up to 4 years post treatment.17, 18 We do not have such studies for accelerated CXL and cannot be certain of its continuing effect. It can be postulated that such an effect of continued flattening may not be observed in accelerated CXL due to its comparatively shallow depth of treatment. It is clear that accelerated CXL is still in its infancy as the treatment parameters have yet to be defined and standardised. There is great variability in treatment settings across studies suggesting that the optimal fluence and timing for accelerated CXL has not been determined. The settings for accelerated CXL differ across studies and also in accordance to the treatment indication. Celik et al23 reported the outcomes of accelerated CXL as an adjuvant treatment to LASIK, using 30 mW/cm2 for 3 min, whereas Kanellopoulos used a setting of 10 mW/cm2 for 3 min as prophylactic treatment in conjunction with LASIK, but used 7 mW/cm2 for 15 min in the treatment of keratoconus,16, 22. More research is needed to determine and standardise the most effective and safe treatment parameters for accelerated CXL. Once this is established, randomised controlled trials would prove invaluable in determining the true efficacy of accelerated CXL and whether accelerated CXL provides at least equal results to conventional CXL. The authors declare no conflict of interest.

14 March 2014 in Eye
Verified
Journal Article
Open access
PDF file
Michael TsatsosMichael Tsatsos
Michael Tsatsos
AKA Konstantopoulos
A Konstantopoulos
PHP Hossain
P Hossain
DAD Anderson
D Anderson
To describe a novel technique for the safe manual dissection of thin donor lenticules in 10 consecutive patients undergoing DSEK surgery. A key element of our new technique was to presoak the donor cornea in balanced salt solution (BSS) for 30 min before manual dissection. The cornea was placed on an artificial anterior chamber and pressure in the chamber was maintained at 80 mm Hg. The limbus of the donor cornea was incised to the same depth as the central corneal thickness. Lamellar dissection was started with the short side of the Morlet dissector (Duckworth & Kent Ltd) and completed using the lamellar (less sharp) end of the Morlet dissector. Outcomes of 10 consecutive cases of thin manually dissected DSEK (TMDSEK) were prospectively analysed for thickness and visual outcome. Mean graft thicknesses measured less than 100 μm at 1 month post surgery (mean thickness 90.7 μm, range 48–137 μm, SD 29.96 μm). Presoaked donor corneal pachymetry was strongly negatively correlated with graft thickness (correlation r=−0.75, P<0.05). Our dissection technique achieves consistently thin endothelial donor corneal grafts that can be safely produced with minimal financial investment and no limitations on surgical time. This technique is likely to be of significant importance for a large proportion of the eye centres where microkeratomes may not be routinely available.